Faculty
Nancy Bartlett.jpg

Nancy L. Bartlett, MD

Professor
Department of Medicine
Oncology Division
Medical Oncology

Research Interests

  • Non-Hodgkin's lymphoma
  • Hodgkin's disease
  • Chronic lymphocytic leukemia

Contact

  • 314-362-5654 (tel)
  • 314-747-5123 (fax)
  • 11th Floor Mid-Campus Center (office)
  • Division of Oncology
    Campus Box 8056
    Washington University Medical School
    660 South Euclid Avenue
    St. Louis, MO 63110

Invited Publications

  • Fine-tuning the treatment of Hodgkin's lymphoma
    Bartlett NL
    N Engl J Med 2016 Jun 23;374(25):2490-2492
  • Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Habermann TM, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wilson L, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2015 Mar;13(3):326-62
  • Blinatumomab for the treatment of B-cell lymphoma
    Oak E, Bartlett NL
    Expert Opin Investig Drugs 2015 May;24(5):715-24
  • Biologic agents in the management of Hodgkin lymphoma
    Rashidi A, Bartlett NL
    J Natl Compr Canc Netw 2015 May;13(5):587-596
  • Lymphomas of the head and neck
    Wang T, Bartlett NL
    In: Cummings Otolaryngology: Head and Neck Surgery. Canada: Elsevier Saunders; 2015; 1805-1815
  • Non-Hodgkin's lymphomas, version 4.2014
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2014 Sep;12(9):1282-303
  • Management of classical Hodgkin lymphoma
    Sanfilippo K, Bartlett NL
    In: Abutalib SA, Markman M. Cancer Consult. Hoboken, NJ: Wiley Blackwell; 2014: 229-234
  • Non-Hodgkin's lymphomas, version 2.2014
    Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H
    J Natl Compr Canc Netw 2014 Jun;12(6):916-46
  • Highlights in lymphoma from the 2013 American Society of Hematology Annual Meeting and Exposition
    Bartlett NL
    Clin Adv Hematol Oncol 2014 Feb;12(2 Suppl 6):18-23
  • Non-Hodgkin's lymphomas, version 1.2013
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M
    J Natl Compr Canc Netw 2013 Mar 1;11(3):257-72; quiz 273
  • Treatment of nodular lymphocyte-predominant Hodgkin lymphoma-"do no harm"
    Bartlett NL
    Clin Adv Hematol Oncol 2013 Jun;11(6):385-7
  • Lymphoma surveillance counterpoint: USA
    Carson KR, Bartlett NL
    In: Johnson FE, Maehara Y, Browman GP, Margenthaler JA, Audisio RA, Thompson JF, Johnson DY, Earle CC, Virgo KS, eds. Patient Surveillance After Cancer Treatment. New York, NY: Humana Press; 2013; 461-466
  • Non-Hodgkin's lymphomas, version 1.2013
    Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M
    J Natl Compr Canc Netw 2013 Mar 1;11(3):257-273
  • Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma
    Foyil KV, Bartlett NL
    Cancer J 2012 Sep;18(5):450-6
  • Where does brentuximab vedotin fit into the management of patients with Hodgkin lymphoma?
    Goyal SD, Bartlett NL
    Curr Hematol Malig Rep 2012 Sep;7(3):179-85
  • Advances in LLM: Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma
    Bartlett NL
    Clin Adv Hematol Oncol 2012 Jul;10(7):468-71
  • Non-Hodgkin's lymphomas
    Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N
    J Natl Compr Canc Netw 2011 May;9(5):484-560
  • Role of routine imaging in lymphoma
    Wagner-Johnston ND, Bartlett NL
    J Natl Compr Canc Netw 2011 May;9(5):575-84
  • Brentuximab vedotin for the treatment of CD30(+) lymphomas
    Foyil KV, Bartlett NL
    Immunotherapy 2011 Apr;3(4):475-85
  • Anti-CD30 antibodies for Hodgkin lymphoma
    Foyil KV, Bartlett NL
    Curr Hematol Malig Rep 2010 Jul;5(3):140-147
  • Something old, something new: options for treating relapsed mantle cell lymphoma
    Wagner-Johnston ND, Bartlett NL
    Oncology (Williston Park) 2009 Jul;23(8):694, 702-3
  • Drug development for recurrent and refractory classical Hodgkin lymphoma
    Wildes TM, Bartlett NL
    Leuk Lymphoma 2009 Apr;50(4):529-40
  • Salvage regimens for Hodgkin lymphoma
    Cashen AF, Bartlett NL
    Clin Adv Hematol Oncol 2008 Jul;6(7):517-24
  • Modern treatment of Hodgkin lymphoma
    Bartlett NL
    Curr Opin Hematol 2008 Jul;15(4):408-14
  • Tumors and masses: lymphoma
    Bartlett NL, Fenske T
    In: Pearson et al (eds), Thoracic Surgery, 3rd ed, WB Saunders Company 2007: 1622-1633
  • Lymphoma
    Bartlett NL, Wagner-Johnston N
    In: Govindan R (ed), The Washington Manual of Oncology, 2nd ed, Lippincott Williams & Wilkins, 2007: 286-303
  • Therapy of relapsed Hodgkin lymphoma
    Cashen AF, Bartlett NL
    Blood Rev 2007 Sep;21(5):233-43
  • Management of advanced Hodgkin's lymphoma: "Not one size fits all."
    Bartlett NL
    In: Perry MC, Govindan R (eds) American Society of Clinical Oncology Educational Book 2006
  • Management of advanced stage Hodgkin's lymphoma
    Smukler AJ, Bartlett NL
    Cancer Treat Res 2006;131:333-52
  • 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma
    Blum KA, Bartlett NL
    Expert Opin Biol Ther 2004 Aug;4(8):1323-31
  • New therapies in Hodgkin's lymphoma
    Bartlett N
    Clin Adv Hematol Oncol 2004 Feb;2(2):80-3
  • Escalated BEACOPP: two steps forward, one step back
    Bartlett NL
    American Journal of Oncology Review 2004;2:119-123
  • Hodgkin's disease: chemotherapy
    Blum KA, Bartlett NL
    In: Rakel R, Bope E, (eds) Conn's Current Therapy, WB Saunders Company, 2004
  • Targeting CD30 in patients with Hodgkin's lymphoma
    Blum KA, Bartlett NL
    Biological Therapy of Lymphoma 2003;6:11-14
  • Antibodies for the treatment of diffuse large cell lymphoma
    Blum KA, Bartlett NL
    Semin Oncol 2003 Aug;30(4):448-56
  • Hodgkin's disease module
    Bartlett NL
    PIER-ACP, 2003
  • Extranodal marginal zone (MALT) lymphoma
    Blum KA, Bartlett NL
    Contemporary Oncology 2002;1:1-8
  • Lymphoma
    Wagner ND, Bartlett NL
    In: Govindan R, Arquette M (eds) The Washington Manual of Oncology, Lippincott Williams & Wilkins, 2002
  • Tumors and masses: lymphoma
    Bartlett NL, Wagner ND
    In: Pearson et al (eds) Thoracic Surgery, 2nd ed, WB Saunders Company, 2002
  • Macroglobulinemia
    Bartlett NL, Arackal SM
    In: Austen FK, Frank MM, Atkinson JP, Cantor H (eds) Samter's Immunologic Diseases, 6th ed, Lippincott Williams & Wilkins, 2001
  • Low grade lymphoma
    Bartlett NL, Horning SJ
    In: Haskell CM (ed) Cancer Treatment, 5th ed, Philadelphia, WB Saunders Company, 2001
  • Treatment advances in non-Hodgkin's lymphoma
    Tan BR, Bartlett NL
    Expert Opin Pharmacother 2000 Mar;1(3):451-66
  • Hodgkin's disease: prognostic factors and short-course regimens
    Bartlett NL, Arackal SM
    Curr Oncol Rep 2000 Mar;2(2):163-71
  • Non-Hodgkin's lymphomas
    Bartlett NL, Wagner ND
    Cancer Chemother Biol Response Modif 1999;18:293-323
  • T-small lymphocyte disorders
    Bartlett NL, Longo DL
    Semin Hematol 1999 Apr;36(2):164-70
  • Hodgkin's disease
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 2nd ed, Philadelphia, WB Saunders Company, 1998
  • Treatment of aggressive histology lymphoma
    Bartlett NL
    Curr Opin Oncol 1997 Sep;9(5):413-9
  • Combined modality therapy
    Bartlett NL, Wasserman TH
    In: Perry MC (ed) Chemotherapy Source Book, 2nd ed, Baltimore, Williams & Wilkens, 109-126; 1996
  • Low grade lymphoma
    Bartlett NL, Horning SJ
    In: Haskell CM (ed) Cancer Treatment, 4th ed, Philadelphia, WB Saunders Company, 1006-1013; 1995
  • Hodgkin's disease
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 1st ed, Philadelphia, WB Saunders Company, 241-50; 1994
  • Composite and discordant lymphomas
    Bartlett NL, Horning SJ
    In: Foley JF, Vose JM, Armitage JO (eds) Current Therapy in Cancer, 1st ed, Philadelphia, WB Saunders Company, 290-94; 1994
  • The modulation of multidrug resistance: clinical studies at stanford
    Fisher GA, Brophy NA, Yahanda AM, Adler KM, Lum BL, Bartlett NL, Halsey J, Sikic BI
    In:  Miyazaki T, Takaku F, Sakurada K (eds) The Mechanism and New Approach on Drug-Resistance of Cancer Cells Proceedings of the International Symposium, Sapporo, Japan: 255-66; 1993
  • Serum markers in germ cell neoplasms
    Bartlett NL, Freiha FS, Torti FM
    Hematol Oncol Clin North Am 1991 Dec;5(6):1245-60